Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06876233 · ClinicalTrials.gov registry record · NA

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

A NA study of Hypertension and Medication Adherence, sponsored by Chad Stecher@asu.edu.

Recruiting
Registry status
NA
Development phase
600
Enrollment target
1
Study location

NCT06876233: Recruiting NA study of Hypertension and Medication Adherence, sponsored by Chad Stecher@asu.edu.

NCT06876233 is a NA study of Hypertension and Medication Adherence that is actively recruiting participants, run by Chad Stecher@asu.edu. The registered enrollment target is 600 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06876233, a NA study of Hypertension and Medication Adherence, is actively recruiting participants, sponsored by Chad Stecher@asu.edu.

RECRUITING
Registry status
NA
Development phase
600 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to determine the effectiveness of a novel mobile health-based habit formation intervention for increasing and maintaining adherence to anti-hypertensive (AH) medication among people living with hypertension and indicate medication nonadherence. The main questions it aims to answer are: * Can daily incentives for AH pill taking increase and maintain AH medication adherence, control blood pressure, and reduce healthcare utilization and costs? * Can daily incentives for AH pill taking, combined with action planning (e.g., "After I drink my morning coffee, I will take my medication.") increase and maintain medication adherence, control blood pressure, and reduce healthcare utilization and costs? * What aspects of daily incentives and/or action planning do participants find most helpful or effective for AH medication adherence? * What barriers exist for participants who receive daily incentives and/or action planning? Researchers will compare three study groups: those who only receive daily incentives for the AH pill taking, those who receive daily incentives for AH pill taking combined with action planning, and a control group (who do not receive daily incentives for AH pill taking or action planning). By comparing these three groups, the researchers will be able to determine the effectiveness of the daily incentives with or without action planning for promoting long-term AH medication adherence, reduce healthcare costs, and improve blood pressure. Participants will: * Complete 5 online surveys over the course of 2 years (baseline, month 4, month 8, month 12, month 24). * Submit blood pressure reading for 7 consecutive days after each survey timepoint. * Submit photo evidence of their AH pill taking for 4 months (intervention groups only). The highest- and lowest-performing participants in each intervention group will also be invited to complete a 30-minute interview to identify additional factors that contributed to either succes

Primary Outcome

The investigators will use Medicaid's prescription data to construct the Primary Outcome of AH medication adherence using the date and supply of pills for each new prescription or refill to determine the number of days in a month a client had pills available. Since refills are often made before an existing prescription ends, the supply of new medications will be counted on days following the last available dose of the prior prescription. The number of days with available AH medication(s) will be

Interventions

  • BEHAVIORAL Wellth App
  • BEHAVIORAL Action Planning
  • BEHAVIORAL Wellth + Cue

Study Locations (1)

California

  • Wellth Inc. - Los Angeles

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2025-09-01
Est. Completion 2029-03-30
Phase NA
Chad Stecher@asu.edu

1 total trials

What NCT06876233 shows while recruiting

NCT06876233 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (83% lower).

The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Wellth App is the first listed.

NCT06876233 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06876233 about?

NCT06876233 is a clinical study titled "Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication". The goal of this clinical trial is to determine the effectiveness of a novel mobile health-based habit formation intervention for increasing and maintaining adherence to anti-hypertensive (AH) medication among people living with hypertension and indicate medication nonadherence. The main questions i...

What is the current status of trial NCT06876233?

This trial is currently recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2025-09-01. Estimated completion is 2029-03-30.

What conditions does trial NCT06876233 study?

This clinical trial studies the following conditions: Hypertension, Medication Adherence, Habits.

What interventions are being tested in trial NCT06876233?

The interventions under investigation include: Wellth App (BEHAVIORAL), Action Planning (BEHAVIORAL), Wellth + Cue (BEHAVIORAL).

Who is sponsoring clinical trial NCT06876233?

This trial is sponsored by Chad Stecher@asu.edu, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06876233 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06876233's enrollment target sits among peer trials

600 101st of 470 higher than 370 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06876233, the US trial registry maintained by the National Library of Medicine. NCT06876233 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.